期刊文献+

体内诱导法建立的Tca8113细胞耐卡铂细胞株的耐药性表达研究

Multidrug Resistance of an in vivo Induced Carboplatin-Resistant Tca8113 Cell Line
下载PDF
导出
摘要 目的探讨通过体内诱导法得到的耐药细胞株的耐药性表达情况。方法以人舌癌Tca8113细胞系为研究对象,实验组采用荷瘤耐药动物的肿瘤细胞培养获得,对照组为体外连续培养诱导其产生耐药性。用四唑蓝法检测细胞耐药指数,标记生物素链亲和素法免疫细胞化学检测耐药相关蛋白P糖蛋白、谷胱甘肽S转移酶π、多药耐药蛋白和拓扑异构酶Ⅱ的表达,逆转录PCR检测多药耐药基因、多药耐药蛋白、拓扑异构酶Ⅱ和谷胱甘肽S转移酶π的表达。结果免疫细胞化学和逆转录PCR显示2组细胞多药耐药蛋白、谷胱甘肽S转移酶π、拓扑异构酶Ⅱ等表达均升高,但体内诱导较体外诱导可以获得更高、更稳定的耐药性。诱导后的Tca8113细胞对氨甲喋呤、卡铂、平阳霉素、长春新碱耐药性明显升高,而对5-氟尿嘧啶耐药性增加不明显。结论体内诱导得到的细胞株耐药性明显高于体外诱导株,肿瘤细胞的耐药现象受多种基因的调节。体内诱导Tca8113卡铂耐药细胞株Tca8113/CBP-vo可以作为肿瘤耐药研究的平台。 Objective To study the drug resistance changes in TcaS113 cell lines by exposing to Carboplatin in the nude mice. Methods The Tca8113 cells were injected subcutaneously in both sides of armpit of nude mice. Two weeks after injection Carboplatin was used subcutaneously around the tumor. Mice were sacrificed about 13 weeks after drug inducing. The sensibility to drugs of the cells was analysed by MTT method. Immunocytochemistry and RT-PCR were utilized to examine the expression of MDR proteins and genes. Results After exposing to Carboplatin, the Tea8113/CBP- vo cells had higher drug-resistance to CBP, MTX, PYM, VCR and higher expression of MRP, GST-π than Tca8113 cells. Conclusion The study showed MDR phenotype was elevated obviously in the inducing group, and in vivo inducing MDR was a good way to establish investigation platform for MDR mechanisms and reversing study.
出处 《广东牙病防治》 2008年第11期495-499,共5页 Journal of Dental Prevention and Treatment
基金 广东省医学科学技术研究基金资助项目(A2005121)
关键词 TCA8113细胞 多药耐药性 体内诱导 卡铂 Tea8113 cell line Multidrug resistance Induction in vivo Carboplatin
  • 相关文献

参考文献10

  • 1冯戈,王大章,陈槐卿,何嘉,冷卫东.人舌鳞癌Tca8113细胞荷瘤裸鼠体内诱导耐药性的实验研究[J].临床口腔医学杂志,2007,23(2):78-81. 被引量:2
  • 2冯戈,王大章,陈槐卿,何嘉,冷卫东.体外诱导Tca8113细胞产生耐药性的分析[J].华西口腔医学杂志,2007,25(2):184-187. 被引量:6
  • 3张萍,王大章,郑光勇,廖楚航.体外短期化疗诱导Tca8113细胞株产生耐药性的研究[J].华西口腔医学杂志,2003,21(1):70-73. 被引量:7
  • 4Bmheim S, Bruland OS, Breistol K, et al. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res, 2004,10(3) :133-141.
  • 5Chang CC, Liang YC, Klutz A, et al. Reversal of multidrug resist-ance by two nordihydroguaiaretic acid derivatives, M4N and maltose- M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol, 2006,58 (5) :640-653.
  • 6Engel JB, Sehally AV, Halmos G, et al. Targeted therapy with a eytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing muhidrug resistance protein MDR-1. Cancer, 2005,104(6) :1312-1321.
  • 7Engel JB, Schally AV, Halmos G, et al. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215 : low induction of muhidrug resistance proteins. Eur J Cancer, 2005,41 (12) : 1824-1830.
  • 8Miraeeo C, Maellaro E, Paeenti L, et al. Evaluation of MDRI, LRP, MRP, and topoisomerase Ⅱ alpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines. Int J Oncol, 2003,23 ( 1 ) :213- 220.
  • 9Wang B, Ngoi S, Wang J, et al. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines. Mol Pharmacol, 2006,70( 1 ) :267-276.
  • 10Weerasinghe P, Hallock S, Tang SC, et al. Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells. Exp Toxicol Pathol, 2006,58( 1 ) :21-30.

二级参考文献20

  • 1[1]Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol, 1996, 148(3): 877-887
  • 2[2]Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst, 1993, 85(8):632-639
  • 3[3]Hu XF, Slater A, Wall DM, et al. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer, 1995, 71(5): 931-936
  • 4[4]Abbaszadegan MR, Futscher BW, Klimecki WT, et al. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res, 1994, 54(17): 4676-4679
  • 5Ramachandran C,Wellham LL.Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts[J].Anticancer Res,2003,23 (3B):2681-90.
  • 6Shionoya M,Jimbo T,Kitagawa M,et al.Tohgo A.DJ-927,a novel oral taxane,overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo[J].Cancer Sci,2003,94(5):459-466.
  • 7Blanc E,Goldschneider D,Ferrandis E,et al.MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model[J].Am J Pathol,2003,163 (1):321-331.
  • 8Warmann SW,Heitmann H,Teichmann B,et al.Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma[J].Pediatric Hematology &Oncology,2005,22 (5):373-386.
  • 9Dupuy M,Blache Y,Bailly C,et al.In vitro and in vivo pharmacological characterisation of the antitumourpropertiesof pyrido[1',2':1,2] imidazo[4,5-h] quinazoline[J].Anticancer Res,2002,22(6A):3365-71.
  • 10Warmann S,Hunger M,Teichmann B,et al.The role of the MDRI gene in the development of multidrug resistance in human hepatoblastoma:clinical course and in vivo model[J].Cancer,2002,95 (8):1795-801.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部